Calderasib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Calderasib is an investigational new drug that is being developed by Merck Sharp & Dohme for the treatment of solid tumors. It targets tumors that express G12C mutated KRAS protein. It has been awarded a breakthrough therapy designation by the U.S. Food and Drug Administration.
Calderasib is an investigational new drug that is being developed by Merck Sharp & Dohme for the treatment of solid tumors. It targets tumors that express G12C mutated KRAS protein. It has been awarded a breakthrough therapy designation by the U.S. Food and Drug Administration.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368211330 under CC BY-SA 4.0; modifications have been made.